P1116: HIGH COMPLETE METABOLIC RESPONSE RATES WITH EPCORITAMAB + R-CHOP IN PREVIOUSLY UNTREATED (1L) PATIENTS WITH HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA, INCLUDING DOUBLE/TRIPLE-HIT: EPCORE NHL-2 UPDATE

• Michael Roost Clausen,
• David Belada,
• Fritz Offner,
• Sven de Vos,
• Joshua Brody,
• Kim Linton,
• Sylvia Snauwaert,
• Raul Cordoba,
• Jun Wu,
• Irina Bykhovski,
• Liwei Wang,
• Ali Rana,
• Lorenzo Falchi

Affiliations

Michael Roost Clausen

1 Vejle Hospital, Vejle, Denmark

David Belada

2 4th Department of Internal Medicine – Hematology, University Hospital and Faculty of Medicine, Hradec Králov, Czech Republic

Fritz Offner

3 Universitair Ziekenhuis Gent, Ghent, Belgium

Sven de Vos

4 Ronald Reagan University of California Los Angeles Medical Center, Los Angeles, United States

Joshua Brody

5 Icahn School of Medicine at Mount Sinai, New York, United States

Kim Linton

6 The Christie NHS Foundation Trust and Manchester Cancer Research Centre, Manchester, United Kingdom

Sylvia Snauwaert

7 Department of Hematology, AZ Sint-Jan Hospital, Bruges, Belgium

Raul Cordoba

8 Fundacion Jimenez Diaz University Hospital, Health Research Institute IIS-FJD, Madrid, Spain

Jun Wu

9 AbbVie, North Chicago, United States

Irina Bykhovski

10 Genmab, Princeton, United States

Liwei Wang

10 Genmab, Princeton, United States

Ali Rana

10 Genmab, Princeton, United States

Lorenzo Falchi

11 Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, United States